Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more
Cytosorbents Corporation (HQE1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, Cytosorbents Corporation (HQE1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cytosorbents Corporation - Net Assets Trend (None–None)
This chart illustrates how Cytosorbents Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cytosorbents Corporation (None–None)
The table below shows the annual net assets of Cytosorbents Corporation from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Cytosorbents Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Cytosorbents Corporation Competitors by Market Cap
The table below lists competitors of Cytosorbents Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Modulight Oyj
HE:MODU
|
$17.65 Million |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
$17.65 Million |
|
Meribank Biotech Co., Ltd
TWO:4724
|
$17.66 Million |
|
Black Iron Inc
PINK:BKIRF
|
$17.66 Million |
|
Jeil Technos Co.Ltd
KQ:038010
|
$17.64 Million |
|
Glidelogic Corp.
PINK:GDLG
|
$17.64 Million |
|
VAA Vista Alegre Atlantis SGPS SA
LS:VAF
|
$17.62 Million |
|
Ai-Media Technologies Ltd
AU:AIM
|
$17.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cytosorbents Corporation's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Cytosorbents Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Cytosorbents Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Cytosorbents Corporation's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cytosorbents Corporation (HQE1) | €- | N/A | N/A | $17.65 Million |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |